INTRODUCTION
Hearing loss, the most common sensory deficit, affects approximately 1/500 newborns. Most congenital and childhood-onset cases are nonsyndromic (70%) and of monogenic origin, with autosomal-recessive inheritance accounting for about 80%. Approximately 20% of patients have autosomal-dominantly inherited forms (ADNSHL). More than 60 ADNSHL loci have been reported. Targeted next-generation sequencing (NGS) of the known deafness genes' exons ("gene panels") is a powerful tool to reveal the disease-causing mutations in patients with hearing loss.
Different mutations in the same Mendelian disease genes may cause distinct-allelic-disorders. They may differ not only clinically but also in their mode of inheritance. Regarding the latter phenomenon, several genes implicated in inherited hearing loss, a condition of extensive genetic heterogeneity, have been associated with both autosomalrecessive and -dominant forms, e.g., GJB2, MYO7A, TMC1, TECTA, MYO6, and TBC1D24. 1 Here, we report cosegregation of a C-terminally located heterozygous nonsense mutation in PTPRQ, a gene implicated in autosomalrecessive deafness, with autosomal-dominant progressive hearing loss in a large family. We propose a locationdependent "shift" of the inheritance mode, possibly due to escape of the mutant transcript from nonsense-mediated decay (NMD). family members III:1, III:2, III:4, and II:2 were investigated by pure-tone audiometry. In children (the index patient, IV:2 and his brother IV:3), pedaudiological investigation included both brain stem electric response audiometry and subjective audiometry. Hearing loss was classified as mild (20-40 dB) , moderate (41-60 dB), severe (61-90 dB), or profound (>90 dB) ( Supplementary Table S1 ).
Next-generation sequencing of a deafness gene panel
Next-generation sequencing (NGS) of the DNA sample of the index patient, IV:2 (Figure 2a ), was conducted for 66 genes (1, 259 coding exons) that have been associated with nonsyndromic hearing loss and selected forms of syndromic hearing loss ( Supplementary Table S2 ) on a MiSeq system (Illumina, San Diego, CA), as previously described. 2 In brief, sheared DNA was ligated to barcoded adaptors for multiplexing. Exons were targeted by an in-solution customized sequence capture library (NimbleGen, Madison, WI). Amplified enriched DNA was subjected to NGS. Reads were mapped against the hg19 human reference genome using Burrows-Wheeler Aligner 3 and processed with SAMtools, 4 Picard (http://picard.sourceforge.net) and Genome Analysis Toolkit. 5 Variants were filtered against dbNSFP v2.0, 6 dbSNP v137, ExAC, 7 the Human Gene Mutation Database (HGMD Professional 2013.2), 8 and the Cologne Center for Genomics in-house database. The cutoff for the maximum minor allele frequency was set to 1%. 9 Nonsense, frameshift and canonical splice site variants were regarded as likely pathogenic. Single-nucleotide variants were assessed using SIFT, 10 MutationTaster, 11 PolyPhen-2, 12 AlignGVGD, 13, 14 Pmut, 15 NNSPLICE v0.9 16 and NetGene2. 17, 18 SeqPilot SeqNext module (v4.0.1, JSI Medical Systems, Ettenheim, Germany) was used for visualization and final assessment of singlenucleotide variants. Sequence data for PTPRQ (MIM 603317) were compared with the reference sequence NM_001145026.1. Schraders et al. 19 have proposed additional PTPRQ exons ( Figure 3c ) that are not contained in NM_001145026.1. All PTPRQ exons, including those described by Schraders et al. and putative additional exons from N-Scan predictions were covered by panel NGS and subsequent Sanger sequencing. Verification of the PTPRQ mutation c.6881G > A (p.Trp2294*) and segregation analyses were carried out by Sanger sequencing. The novel PTPRQ mutation described herein has been submitted to the Leiden Open Variation Database 20 (http://databases.lovd.nl/shared/genes/ptprq).
Genome-wide linkage analysis
DNA was extracted from peripheral blood samples using standard methods. DNA samples of 11 individuals (seven affected individuals from four generations, including the young proband with occasional "borderline" audiometry results, IV:3; Supplementary Table S1 ) were subjected to genome-wide linkage analysis using the Infinium CoreExome-24 v1.1 BeadChip (Illumina) according to the manufacturer's protocol. Subsequent data handling was performed using the graphical user interface ALOHOMORA. 21 Relationship errors were identified by using the program Graphical Relationship Representation. 22 The program PedCheck was applied to find Mendelian errors, 23 and data for single-nucleotide polymorphisms (SNPs) with such errors were removed. Non-Mendelian errors were identified by using the program MERLIN 24 and unlikely genotypes for related samples were deleted. Linkage analysis was performed assuming autosomaldominant inheritance, full penetrance, and a disease gene frequency of 0.0001. Multipoint logarithm of the odds (LOD) scores were calculated using the program ALLEGRO. 25 Haplotypes were reconstructed with ALLEGRO and presented graphically with HaploPainter. 26 
Whole-exome sequencing
Whole-exome sequencing (WES) was performed after enrichment with Roche/NimbleGen technology (SeqCap EZ Exome v2.0 Library) in a pool of 10 samples on an Illumina 1500 instrument in rapid mode (TruSeq Rapid SBS chemistry v1). WES data were analyzed with a focus on the mapped candidate region on chromosome 12 including PTPRQ, but also beyond that region ( Supplementary Table S2 ).
Semiquantitative reverse-transcriptase polymerase chain reaction
Fibroblast cell lines derived from skin biopsies of a control subject and patient III:2 were established and maintained in culture at 37°C, 5% CO 2 in Dulbecco's Modified Eagle Medium supplemented with 10% fetal calf serum, 1% penicillin/streptomycin, and 0.75 μg/ml amphotericin B. 2 × 10 5 fibroblasts were seeded in triplicates in a six-well plate. The following day, RNA was extracted according to the manufacturer's protocol (RNeasy Mini Kit, Qiagen, Hilden, Germany). 600 ng of fibroblast RNA was retrotranscribed using the QuantiTect Reverse Transcription Kit (Qiagen) and complementary DNA was diluted with TE − 4 buffer to 20 ng/ μl. Semiquantitative reverse-transcription polymerase chain reaction were carried out using recombinant Taq DNA Polymerase (Invitrogen, Waltham, MA, USA) in a BioRad C1000 Touch Thermal Cycler (Biorad, Hercules, CA, USA). For details regarding polymerase chain reaction conditions and primers, see Supplementary Table S4 . Samples were run in a 1.5% agarose gel and visualized with a BioRad Chemidoc XRS system. Analysis was performed using ImageLab 5.2.1 (BioRad) and statistical analysis using MS Excel 2013 (Student's t-test).
RESULTS

Characterization of hearing loss in a four-generation ADNSHL family
The initial pedaudiological investigation of the index patient, IV:2, at the age of 2½ years was carried out because of delayed language development. A mild to severe bilateral sensorineural hearing loss was found and bilateral conventional hearing aids were put in use. Family members carrying the PTPRQ mutation were found to be affected by hearing loss with variable age of onset (early childhood to third decade) and variable course, as is particularly apparent in the patient's mother, maternal grandmother, maternal great-grandmother, and great-aunt and her son ( Supplementary Table S1 , Figure 1 ). Results from pedaudiologic assessment in a young male carrier of the mutation (IV:3, last audiology exam performed at the age of 4 years) fluctuated between borderline mild hearing impairment and normal hearing ( Supplementary Table S1 ). Individuals III:1, III:2, and IV:1-4 were personally examined by clinical geneticists and had normal body measurements, no specific minor anomalies, and no additional major health issues. The other affected individuals (I:2, II:2, II:3, II:5, and III:4) were reportedly otherwise healthy as well.
A novel PTPRQ nonsense mutation, located in a mapped chromosome 12 candidate region, cosegregates with ADNSHL Targeted NGS of known autosomal-recessive nonsyndromic hearing loss and ADNSHL genes in the index patient (IV:2) revealed a heterozygous nonsense mutation, c.6881G > A (p. Trp2294*) ( Figure 2c ), in the last coding exon of PTPRQ (NM_001145026.1), encoding a type III receptor-like protein tyrosine phosphatase ( Figure 3a ). The p.Trp2294* mutation, which was neither present in ExAC nor in the gnomAD, cosegregated with hearing loss in the family. Additionally, linkage analysis applying genome-wide SNP mapping revealed a single genomic region with the maximum parametric LOD score of 2.4 (when including IV:3 as affected; the LOD score is 2.1 when IV:3 is excluded from the calculation) that includes the PTPRQ gene (12q21.2-12q22) (Figure 2b,d) . Following the identification of the causative mutation in PTPRQ, DFNA73 (MIM 617663) was assigned as a novel locus designation for ADNSHL by OMIM.
Exclusion of secondary mutations in PTPRQ
NGS and Sanger sequencing of all PTPRQ exons, including previously described alternatively spliced 5′ exons, 19 did not identify any other mutation (Table 1, Figure 3b,d) .
Furthermore, NGS of all N-SCAN-predicted potential coding regions of a putative "extended" PTPRQ transcript did not detect another pathogenic aberration ( Figure 3c ).
Assessment of variants in other genes of the mapped 12q locus
WES of the index patient identified another heterozygous nonsense variant, c.4948delA (p.Met1650*), in the LRRIQ1 gene, encoding a leucine-rich repeats and IQ motif containing protein, in the mapped candidate locus on chromosome 12. The c.4948delA (p.Met1650*) variant is listed in dbSNP (rs763597988), but it is rare (one heterozygous individual annotated in the ExAC database, corresponding to a minor allele frequency of 0.0008%). It was present in heterozygous state in two individuals with normal hearing, the youngest sibling (IV:4) of the index patient and his oldest brother (IV:1), and in their father (III:1). Patient III:1 was not aware of his mild hearing loss affecting the high frequencies, which was accidentally diagnosed by us in the course of the audiologic characterization of the family. It was not found in the patient's mother or her affected relatives. The localization of LRRIQ1 in the mapped candidate locus was thus coincidental and did not reflect linkage with the phenotype in the index patient's mother's family. However, it cannot be excluded that it contributes to or even causes the mild hearing loss in the index patient's father, and that hearing impairment might manifest in the two healthy carriers of the LRRIQ1 variant at an older age.
The WES analysis did not reveal clearly pathogenic variants in known deafness genes (apart from PTPRQ) or in potential candidate genes, particularly not in the chromosome 12 region identified by linkage analysis ( Table 1 , Supplementary  Table S3 ). Two heterozygous variants were identified in two other genes from the mapped 12q region, SYT1 and TMTC2. Both variants have allele frequencies in the general population above the threshold for autosomal-dominant mutations, and homozygous occurrence in healthy individuals has been documented for both (ExAC database). PTPRQ transcripts harboring the c.6881G > A variant do not undergo NMD Due to the low expression of PTPRQ in whole blood samples, we quantified its expression in a patient-derived fibroblast cell line and compared it with a control (Figure 4a ). Quantitative analysis for an N-terminal (encompassing exon 2) and a C-terminal PTPRQ (encompassing exon 45) region showed no differential expression between the cell lines. This demonstrates that the mutated allele escapes NMD and supports the hypothesis that a truncated PTPRQ protein is produced.
DISCUSSION
Biallelic PTPRQ mutations have been reported to cause nonsyndromic autosomal-recessive, but not autosomal-dominant, deafness with vestibular dysfunction (DFNB84A, MIM 613391). 19 Here, we report the most C-terminally located PTPRQ mutation to date, c.6881G > A (p.Trp2294*) in the gene's last exon, exon 45, cosegregating with ADNSHL in a large German family. The mammalian NMD surveillance system cannot differentiate between nonsense mutations in the penultimate exon located less than~55 bp from the final intron or in the last exon and natural stop codons in the last exon. 27 In contrast to recessive PTPRQ mutations, which have been proposed to cause DFNB84A via a loss-of-function mechanism, 28 messenger RNA carrying c.6881G > A (p.Trp2294*) would probably escape NMD and generate a protein lacking the six C-terminal residues, which may exert a dominant-negative effect. Of note, only one other reported PTPRQ mutation, homozygous c.6775delC in exon 44 in an autosomal-recessive inheritance nonsyndromic hearing loss family, 29 affects one of the two last exons. In contrast to the nonsense mutation discussed in our study, a protein generated from this Thr Thr
Met STOP PTPRQ  MYF5  BC037383  AK022997  LIN7A  LIN7A  MIR617  MIR618  MIR4699  PPFIA2  PPFIA2  PPFIA2  PPFIA2  PPFIA2  PPFIA2  PPFIA2  PPFIA2   MYF6  ACSS3  ACSS3  ACSS3   CCDC59  CCDC59  METTL25  TMTC2  TMTC2  TMTC2  TMTC2 U6 frameshift mutation would be extremely elongated (p. Leu2259Serfs*99), compatible with a recessive loss-offunction allele. We propose a genotype-phenotype correlation reminiscent of (throughout truncating) DIAPH1 mutations causing dominant hearing loss only when located in a short stretch of the penultimate exon or its donor splice site, 30 and recessive disease if situated more N-terminally. 31 PTPRQ encodes protein tyrosine phosphatase receptor Q and has been found to be identical with the 275-kDa hair-cell antigen, a component of hair-bundle interstereocilial shaft connectors. As such, mouse Ptprq has been shown to be required for the maturation of the hair bundle. 28, 32 Ptprq is downregulated in mice with a heterozygous or homozygous point mutation in the seed region of miR-96, a microRNA regulating several genes required for hearing and whose mutations are implicated in inherited hearing loss in mice and humans. 33, 34 It is yet unknown if PTPRQ forms dimers, as has been shown for a related protein, PTPRO. 35 Interference with the normal protein deduced from the wild-type allele (dominant negative), but also the gain of a novel toxic function, are potential mechanisms of the assumingly autosomal-dominant C-terminal PTPRQ mutation reported herein. The loss of the C-terminal six amino acid residues could also prevent binding of intracellular interaction partners.
When assessing the potential pathogenicity of variants identified via NGS of a disease gene panel, variants in genes that have so far not been linked to the inheritance mode suspected in the given patient should also be considered. We therefore conducted segregation analysis for a heterozygous nonsense mutation in a recessive disease gene, PTPRQ, in a family with apparently dominant transmission of hearing loss. Based on current knowledge, this mutation could have been considered only as a carriership for a recessive mutation, and thus discarded without further verification. Additional WES and linkage analysis support the categorization of the C-terminal PTPRQ mutation as the diseasecausing dominant mutation in this family; no other convincing candidate variant was identified, neither in NGS of the deafness gene panel nor in WES ( Table 1 , Supplementary  Table S3 ), and importantly, the PTPRQ mutation is localized in the mapped chromosomal candidate region. Our findings indicate a "novel" mode of inheritance for PTPRQ mutations. Consequently, PTPRQ should be included in genetic diagnostic testing not only in patients with prelingual recessive deafness, but also in patients with hearing loss of variable age of onset and family history suggesting autosomaldominant inheritance. Analogous to the apparent genotypephenotype correlation in DFNA1, truncating mutations in the The upper part (filter 1) lists variants, including the PTPRQ nonsense mutation, located in the chromosomal candidate region identified via genome-wide linkage analysis. filter 3 (lower part) analyzed for variants in genes knowingly associated with inherited hearing impairment.
penultimate and in the last PTPRQ exon should receive special attention in that respect. Patient IV:3 (4 years of age) carries the mutation and shows fluctuating results (from borderline to normal hearing) in audiologic assessment. However, considering the variable age of onset of the other PTPRQ mutation carriers in the family, he is likely to develop hearing impairment in the future. Our suggestion of PTPRQ as a candidate for autosomal-dominant hearing loss is strongly supported by the results of extensive genetic, but not protein, analyses. Analysis of protein function could further verify PTPRQ as an ADNSHL candidate gene, but would be complicated not only by the large size of the protein, but also because mutant PTPRQ Trp2294* would differ from the wild type by just six residues. We therefore quantified PTPRQ expression, and our findings support the hypothesis of a truncated "disease-causing" PTPRQ protein derived from the c.6881G > A (p.Trp2294*) transcript.
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